[Present and future of home anti-cancer chemotherapy for unresectable recurrence of XXXX ].

@entity1 @entity1726 @entity14 @entity99 @entity1487
Continuous @entity99 ( @entity99 ) was performed for 100 @entity14 @entity1 with unresectable liver metastases in our outpatient clinic. The administration schedule was @entity1487 250 mg/day for 7 days every other week. In this study, 93 cases were evaluable. The average dose of @entity1487 was 24 g (3.0-66.5 g). The response rate was 59.1% (CR: 4 cases, PR: 51 cases, NC: 12 cases and @entity1726 : 26 cases). The prognostic outcome was significantly prolonged in the effective cases (50% survival duration was as follows: CR: 764 days, PR: 620 days, NC: 255 days and @entity1726 : 152 days). The complication rate with @entity99 was 15.1%, but nobody died from these complications. Hepatectomy after @entity99 was performed in 19 cases (20.4%) because of the effect of @entity99 . The three-year survival rate was 35.3% for @entity99 with hepatectomy and 3.8% for only @entity99 . There was statistically significant difference (p < 0.0001) between these two groups. Hepatectomy after @entity99 is a new strategy for unresectable liver metastasis of @entity14 . Recently, we performed home systemic chemotherapy using @entity1487 for 3 recurrent @entity1 of @entity14 and were able to continue this therapy safely for more than 2 months.
